Abstract
A case of severe bone marrow inhibition in the treatment of differentiated thyroid cancer (DTC) by radionuclide 131I was reported. The characteristics of the case were analyzed based on clinical diagnosis, changes in bone marrow hematopoietic system, and whether the patient's treatment process was standardized. The therapeutic effect of radionuclide 131I in the diagnosis and treatment of DTC bone metastasis and the effect of bone marrow hematopoiesis were reviewed. Radionuclide 131I had considerable clinical effect on the diagnosis and treatment of DTC bone metastasis. However, with the increase of cumulative dose and the difference of sensitivity of patients to 131I treatment, white blood cells or platelets in the bone marrow hematopoietic system may decrease. For the treatment of 131I patients with extensive bone metastasis, the occurrence of bone marrow inhibition should be on highly alert and the cumulative treatment dose should be considered. The interval between retreatment should be maximized. When bone marrow inhibition occurs in patients with extensive bone metastasis, 131I treatment should be used selectively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
